liraglutide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
glucagon-like peptide (GLP) analogues and agonists 4164 204656-20-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • saxenda
  • liraglutide [rDNA origin]
  • liraglutide rDNA origin
  • liraglutide [rNDA origin] injection
  • liraglutide
  • NN2211
  • victoza
  • liraglutide recombinant
An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.
  • Molecular weight: 3751.26
  • Formula: C172H265N43O51
  • CLOGP:
  • LIPINSKI: None
  • HAC: 94
  • HDO: 54
  • TPSA: 1513.76
  • ALOGS:
  • ROTB: 130

Drug dosage:

DoseUnitRoute
40 U P
1.50 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 6 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance) 0.01 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.10 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Jan. 20, 2010 PMDA Novo Nordisk Pharma Ltd
June 30, 2009 EMA
Jan. 25, 2010 FDA NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 2244.02 14.43 812 24625 69014 90533996
Pancreatitis acute 723.72 14.43 289 25148 31826 90571184
Nausea 663.96 14.43 1140 24297 1109176 89493834
Pancreatic carcinoma 467.83 14.43 148 25289 8229 90594781
Diabetic ketoacidosis 389.78 14.43 172 25265 24235 90578775
Vomiting 356.98 14.43 721 24716 787572 89815438
Blood glucose increased 318.78 14.43 242 25195 95004 90508006
Lipase increased 310.48 14.43 117 25320 10994 90592016
Cholelithiasis 206.19 14.43 147 25290 52359 90550651
Eructation 181.15 14.43 79 25358 10803 90592207
Injection site urticaria 171.47 14.43 89 25348 17922 90585088
Hypoglycaemia 171.11 14.43 148 25289 69700 90533310
Abdominal pain 170.92 14.43 356 25081 395365 90207645
Injection site rash 165.31 14.43 96 25341 24077 90578933
Injection site erythema 163.18 14.43 168 25269 98334 90504676
Diabetes mellitus inadequate control 151.59 14.43 83 25354 18601 90584409
Pancreatic carcinoma metastatic 149.23 14.43 46 25391 2342 90600668
Glycosylated haemoglobin increased 137.04 14.43 73 25364 15489 90587521
Lactic acidosis 133.95 14.43 112 25325 50351 90552659
Diarrhoea 131.16 14.43 565 24872 938625 89664385
Dehydration 128.03 14.43 210 25227 194237 90408773
Weight decreased 121.89 14.43 304 25133 379606 90223404
Injection site pruritus 121.67 14.43 109 25328 53725 90549285
Blood glucose decreased 121.59 14.43 78 25359 23351 90579659
Euglycaemic diabetic ketoacidosis 116.33 14.43 49 25388 6152 90596858
Ketoacidosis 114.36 14.43 47 25390 5548 90597462
Papillary thyroid cancer 100.86 14.43 35 25402 2592 90600418
Amylase increased 100.60 14.43 46 25391 7026 90595984
Medullary thyroid cancer 97.83 14.43 21 25416 241 90602769
Weight loss poor 90.99 14.43 28 25409 1417 90601593
Thyroid mass 89.52 14.43 39 25398 5316 90597694
Acute kidney injury 87.95 14.43 242 25195 320145 90282865
Systemic lupus erythematosus 84.82 14.43 4 25433 361892 90241118
Pemphigus 78.64 14.43 3 25434 326861 90276149
Glossodynia 77.25 14.43 3 25434 321776 90281234
Thyroid neoplasm 72.85 14.43 31 25406 3990 90599020
Adenocarcinoma pancreas 70.73 14.43 22 25415 1154 90601856
Contraindicated product administered 70.55 14.43 5 25432 320134 90282876
Joint swelling 69.84 14.43 27 25410 503273 90099737
Thyroid cancer 68.39 14.43 34 25403 6250 90596760
Impaired gastric emptying 62.42 14.43 41 25396 12768 90590242
Injection site reaction 61.26 14.43 100 25337 91980 90511030
Constipation 60.90 14.43 195 25242 280200 90322810
Pericarditis 60.16 14.43 4 25433 270147 90332863
Infusion related reaction 58.40 14.43 22 25415 416758 90186252
Abdominal distension 56.74 14.43 118 25319 130483 90472527
Cholecystitis 56.25 14.43 43 25394 16997 90586013
Arthropathy 53.57 14.43 18 25419 366224 90236786
Drug dose titration not performed 53.05 14.43 16 25421 756 90602254
Decreased appetite 52.52 14.43 227 25210 376313 90226697
Helicobacter infection 51.58 14.43 3 25434 226847 90376163
Flatulence 50.20 14.43 60 25377 41307 90561703
Abdominal pain upper 49.05 14.43 204 25233 332470 90270540
Pancreatic neoplasm 48.88 14.43 16 25421 990 90602020
Injection site haematoma 48.66 14.43 28 25409 6894 90596116
Treatment failure 46.10 14.43 14 25423 303914 90299096
Wound 45.88 14.43 14 25423 302966 90300044
Folliculitis 45.56 14.43 3 25434 204350 90398660
Pyrexia 45.54 14.43 72 25365 660413 89942597
Stomatitis 42.86 14.43 12 25425 274686 90328324
Therapeutic product effect decreased 41.71 14.43 13 25424 277558 90325452
Palpitations 39.15 14.43 105 25332 136623 90466387
Rheumatoid arthritis 39.06 14.43 27 25410 362587 90240423
General physical health deterioration 38.84 14.43 26 25411 355089 90247921
Drug ineffective 38.45 14.43 230 25207 1384068 89218942
Blister 38.21 14.43 12 25425 254986 90348024
Reversible cerebral vasoconstriction syndrome 38.13 14.43 20 25417 4110 90598900
Injection site pain 37.85 14.43 121 25316 173578 90429432
Hyperglycaemia 37.53 14.43 58 25379 50912 90552098
Impaired healing 36.96 14.43 10 25427 234189 90368821
Cholecystitis acute 36.13 14.43 26 25411 9378 90593632
Injury 36.10 14.43 6 25431 197343 90405667
Drug intolerance 35.60 14.43 44 25393 447547 90155463
Pancreatitis necrotising 35.48 14.43 16 25421 2365 90600645
Pancreatic enzymes increased 34.98 14.43 12 25425 858 90602152
Renal failure 34.91 14.43 98 25339 130909 90472101
Hepatic enzyme increased 34.86 14.43 30 25407 360706 90242304
Obstructive pancreatitis 33.77 14.43 11 25426 670 90602340
Bile acid malabsorption 33.28 14.43 9 25428 286 90602724
Cholecystectomy 33.07 14.43 27 25410 11728 90591282
Biliary colic 32.81 14.43 18 25419 4045 90598965
Type 2 diabetes mellitus 31.47 14.43 9 25428 203235 90399775
Pancreatic mass 31.11 14.43 12 25425 1199 90601811
Drug titration error 30.86 14.43 12 25425 1225 90601785
Pancreatic cyst 30.26 14.43 14 25423 2196 90600814
Pain 30.03 14.43 161 25276 996180 89606830
Irritable bowel syndrome 28.94 14.43 11 25426 207437 90395573
Hepatic steatosis 28.55 14.43 43 25394 36902 90566108
Febrile neutropenia 28.55 14.43 5 25432 158344 90444666
Swelling 28.54 14.43 46 25391 419012 90183998
Infection 28.35 14.43 36 25401 362058 90240952
Musculoskeletal stiffness 28.23 14.43 25 25412 296507 90306503
C-reactive protein increased 28.14 14.43 8 25429 181381 90421629
Lower respiratory tract infection 27.87 14.43 18 25419 250641 90352369
Non-cardiogenic pulmonary oedema 27.48 14.43 11 25426 1213 90601797
Joint range of motion decreased 27.47 14.43 3 25434 135640 90467370
Bile duct stone 27.24 14.43 16 25421 4091 90598919
Injection site bruising 27.22 14.43 51 25386 52256 90550754
Ill-defined disorder 27.16 14.43 9 25428 184882 90418128
Blood glucose abnormal 27.12 14.43 22 25415 9470 90593540
Cholangiocarcinoma 26.81 14.43 11 25426 1292 90601718
Goitre 26.66 14.43 19 25418 6748 90596262
Neutropenia 26.61 14.43 15 25422 224889 90378121
Mobility decreased 26.55 14.43 19 25418 250715 90352295
Glycosylated haemoglobin decreased 26.29 14.43 9 25428 640 90602370
Diverticulitis intestinal perforated 25.97 14.43 8 25429 406 90602604
Liver injury 25.59 14.43 8 25429 170559 90432451
Pneumonia 24.64 14.43 94 25343 637965 89965045
Blood cholesterol increased 24.43 14.43 14 25423 207998 90395012
Hypoglycaemic unconsciousness 24.29 14.43 9 25428 805 90602205
Fibromyalgia 24.06 14.43 14 25423 206255 90396755
Ductal adenocarcinoma of pancreas 23.68 14.43 6 25431 147 90602863
Injection site nodule 23.47 14.43 15 25422 4458 90598552
Increased appetite 23.03 14.43 22 25415 11743 90591267
Breast cancer 22.66 14.43 48 25389 53713 90549297
Disease progression 22.35 14.43 8 25429 156607 90446403
Maternal exposure during pregnancy 22.25 14.43 42 25395 360021 90242989
Hypertension 22.10 14.43 61 25376 457471 90145539
Gastritis 22.08 14.43 41 25396 41712 90561298
Mental disability 22.06 14.43 6 25431 195 90602815
Lack of satiety 21.54 14.43 3 25434 0 90603010
Pancreatic operation 21.54 14.43 3 25434 0 90603010
Injection site swelling 21.36 14.43 50 25387 59789 90543221
Abortion spontaneous 21.33 14.43 47 25390 54009 90549001
Glomerular filtration rate decreased 21.27 14.43 25 25412 16907 90586103
Genotype drug resistance test positive 21.25 14.43 7 25430 442 90602568
Dysgeusia 21.09 14.43 46 25391 52514 90550496
Nephrolithiasis 20.89 14.43 44 25393 49041 90553969
Lung disorder 20.81 14.43 8 25429 149875 90453135
Incision site swelling 20.01 14.43 6 25431 278 90602732
Aerococcus urinae infection 19.46 14.43 3 25434 3 90603007
Huerthle cell carcinoma 19.46 14.43 3 25434 3 90603007
Blood calcitonin increased 19.42 14.43 4 25433 37 90602973
Wheezing 19.33 14.43 23 25414 238057 90364953
Pancytopenia 19.22 14.43 5 25432 120258 90482752
Diabetic retinopathy 19.18 14.43 11 25426 2691 90600319
Nasopharyngitis 19.12 14.43 55 25382 407049 90195961
Metabolic alkalosis 18.86 14.43 12 25425 3537 90599473
White blood cell count decreased 18.57 14.43 12 25425 167097 90435913
Suicidal ideation 18.45 14.43 54 25383 73801 90529209
Genital burning sensation 18.43 14.43 6 25431 365 90602645
Gastroenteritis 18.43 14.43 31 25406 29198 90573812
Diabetic neuropathy 18.38 14.43 13 25424 4561 90598449
Bursitis 18.32 14.43 7 25430 131647 90471363
Thrombocytopenia 18.22 14.43 19 25418 208706 90394304
Malignant neoplasm progression 17.95 14.43 4 25433 106866 90496144
Night sweats 17.67 14.43 7 25430 128759 90474251
Metastases to liver 17.43 14.43 30 25407 28777 90574233
Toxicity to various agents 17.41 14.43 34 25403 287812 90315198
Injection site irritation 17.31 14.43 14 25423 6001 90597009
Benign neoplasm of thyroid gland 17.24 14.43 8 25429 1263 90601747
Pancreatic pseudocyst 17.18 14.43 7 25430 808 90602202
Anuria 17.17 14.43 21 25416 14797 90588213
Sinusitis 17.11 14.43 45 25392 343043 90259967
Gallbladder disorder 16.67 14.43 24 25413 19779 90583231
Dermoid cyst 16.58 14.43 6 25431 502 90602508
Pancreatitis chronic 16.08 14.43 10 25427 2833 90600177
Discomfort 16.08 14.43 33 25404 274302 90328708
Diabetic ketosis 16 14.43 6 25431 555 90602455
Sinoatrial block 15.76 14.43 7 25430 998 90602012
Dizziness 15.62 14.43 242 25195 589042 90013968
Inappropriate schedule of product administration 15.49 14.43 83 25354 149850 90453160
Completed suicide 15.34 14.43 11 25426 145047 90457963
Injection site cyst 15.11 14.43 4 25433 117 90602893
Imminent abortion 15.06 14.43 3 25434 23 90602987
Blood glucose fluctuation 14.98 14.43 12 25425 5071 90597939
Contusion 14.91 14.43 30 25407 251186 90351824
Product storage error 14.85 14.43 23 25414 20218 90582792
Somnambulism 14.83 14.43 13 25424 6215 90596795
Osteoarthritis 14.75 14.43 20 25417 195710 90407300
Fungal infection 14.53 14.43 35 25402 42626 90560384

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 1703.75 17.07 675 19859 42593 42558208
Pancreatitis acute 493.77 17.07 265 20269 33299 42567502
Pancreatic carcinoma 417.30 17.07 161 20373 9345 42591456
Nausea 305.19 17.07 620 19914 396179 42204622
Diabetic ketoacidosis 285.69 17.07 161 20373 22206 42578595
Neuritis 240.03 17.07 96 20438 6124 42594677
Pulmonary vasculitis 232.43 17.07 94 20440 6172 42594629
Pancreatic carcinoma metastatic 218.80 17.07 75 20459 3091 42597710
Lipase increased 215.10 17.07 104 20430 10462 42590339
Eosinophilic granulomatosis with polyangiitis 203.39 17.07 94 20440 8544 42592257
Neurological symptom 202.35 17.07 98 20436 9893 42590908
Total lung capacity abnormal 186.91 17.07 73 20461 4370 42596431
Blood glucose increased 176.70 17.07 197 20337 73502 42527299
Respiratory symptom 175.24 17.07 92 20442 11014 42589787
Pulmonary alveolar haemorrhage 158.23 17.07 95 20439 14721 42586080
Forced expiratory volume decreased 158.00 17.07 76 20458 7554 42593247
Vomiting 156.03 17.07 394 20140 289329 42311472
Mite allergy 154.42 17.07 66 20468 4980 42595821
Mycotic allergy 153.07 17.07 65 20469 4826 42595975
Dust allergy 150.92 17.07 66 20468 5266 42595535
Conjunctivitis allergic 147.54 17.07 67 20467 5844 42594957
Spirometry abnormal 146.63 17.07 64 20470 5082 42595719
Vasculitis 144.17 17.07 97 20437 18297 42582504
Diabetes mellitus inadequate control 142.25 17.07 90 20444 15300 42585501
Antineutrophil cytoplasmic antibody positive 139.90 17.07 59 20475 4306 42596495
Glycosylated haemoglobin increased 130.62 17.07 80 20454 12844 42587957
Obstructive airways disorder 122.62 17.07 99 20435 24660 42576141
Normochromic normocytic anaemia 120.65 17.07 67 20467 8964 42591837
Sleep disorder due to a general medical condition 117.88 17.07 84 20450 17369 42583432
Pulmonary fibrosis 116.14 17.07 99 20435 26582 42574219
Hypothyroidism 109.91 17.07 104 20430 31980 42568821
Adenocarcinoma pancreas 109.52 17.07 37 20497 1457 42599344
Nodule 107.66 17.07 70 20464 12464 42588337
Full blood count abnormal 102.63 17.07 97 20437 29779 42571022
Arteriosclerosis 99.97 17.07 77 20457 17912 42582889
Cholelithiasis 92.27 17.07 82 20452 23264 42577537
Lactic acidosis 88.39 17.07 109 20425 45152 42555649
Eructation 88.10 17.07 46 20488 5440 42595361
Arteriosclerosis coronary artery 84.75 17.07 71 20463 18606 42582195
Amylase increased 76.66 17.07 45 20489 6684 42594117
Abdominal pain 76.37 17.07 233 20301 190238 42410563
Toxicity to various agents 74.27 17.07 11 20523 229125 42371676
Haemoptysis 74.22 17.07 101 20433 46066 42554735
Lung disorder 72.78 17.07 102 20432 47821 42552980
Weight decreased 71.22 17.07 241 20293 207707 42393094
Hypoglycaemia 64.93 17.07 109 20425 59745 42541056
Febrile neutropenia 64.80 17.07 7 20527 185696 42415105
Loss of personal independence in daily activities 62.61 17.07 97 20437 49719 42551082
Capillaritis 61.17 17.07 27 20507 2201 42598600
Asthma 60.43 17.07 108 20426 62206 42538595
Papillary thyroid cancer 60.31 17.07 20 20514 743 42600058
Injection site rash 59.34 17.07 36 20498 5676 42595125
Wheezing 58.40 17.07 99 20435 54682 42546119
Diarrhoea 57.68 17.07 399 20135 460450 42140351
Drug ineffective 57.48 17.07 138 20396 630059 41970742
Pancreatitis chronic 57.14 17.07 26 20508 2276 42598525
Pneumonia 56.00 17.07 73 20461 422076 42178725
Neutropenia 55.28 17.07 14 20520 199417 42401384
Pancreatitis necrotising 54.07 17.07 29 20505 3620 42597181
Ketoacidosis 53.73 17.07 33 20501 5319 42595482
Therapeutic product effect incomplete 51.73 17.07 109 20425 70830 42529971
Thyroid cancer 50.22 17.07 22 20512 1761 42599040
Abdominal pain upper 50.20 17.07 118 20416 82491 42518310
Weight loss poor 49.69 17.07 13 20521 206 42600595
Acute kidney injury 48.83 17.07 323 20211 367014 42233787
Medullary thyroid cancer 47.85 17.07 10 20524 54 42600747
Pyrexia 47.41 17.07 73 20461 393969 42206832
Product use in unapproved indication 42.25 17.07 18 20516 184438 42416363
Injection site haematoma 39.31 17.07 19 20515 1906 42598895
Respiratory tract haemorrhage 38.44 17.07 17 20517 1392 42599409
Thrombocytopenia 38.39 17.07 22 20512 190257 42410544
Diabetic metabolic decompensation 37.73 17.07 19 20515 2083 42598718
Pancreatic neoplasm 37.44 17.07 15 20519 959 42599842
Thyroid mass 36.43 17.07 14 20520 801 42600000
Gastrooesophageal reflux disease 34.94 17.07 71 20463 44952 42555849
Metastases to liver 34.59 17.07 41 20493 16285 42584516
Disease progression 34.55 17.07 13 20521 143643 42457158
Dyspepsia 34.24 17.07 67 20467 41285 42559516
White blood cell count decreased 34.15 17.07 6 20528 110390 42490411
Cholecystectomy 31.83 17.07 20 20514 3354 42597447
Pancreatic pseudocyst 31.76 17.07 13 20521 879 42599922
Anxiety 31.72 17.07 127 20407 118433 42482368
Pancreatic carcinoma stage IV 31.70 17.07 14 20520 1142 42599659
Platelet count decreased 30.96 17.07 14 20520 138567 42462234
Pancreatic mass 30.73 17.07 13 20521 955 42599846
Blood glucose decreased 30.60 17.07 36 20498 14183 42586618
Productive cough 30.58 17.07 73 20461 51494 42549307
Dehydration 30.37 17.07 142 20392 141625 42459176
Death 28.29 17.07 124 20410 471061 42129740
Abdominal discomfort 28.16 17.07 90 20444 75165 42525636
Follicular thyroid cancer 28.05 17.07 5 20529 9 42600792
Off label use 27.87 17.07 187 20347 638148 41962653
Extrasystoles 27.81 17.07 20 20514 4189 42596612
Injection site erythema 27.73 17.07 41 20493 20154 42580647
Tonsillar ulcer 27.61 17.07 8 20526 188 42600613
Injection site pruritus 27.54 17.07 28 20506 9377 42591424
Cholangiocarcinoma 26.99 17.07 14 20520 1632 42599169
Supraventricular extrasystoles 26.39 17.07 19 20515 3987 42596814
Malignant neoplasm progression 25.74 17.07 10 20524 108390 42492411
Decreased appetite 25.65 17.07 170 20364 192967 42407834
Blood calcitonin increased 24.96 17.07 5 20529 21 42600780
Thyroid neoplasm 24.39 17.07 9 20525 460 42600341
Anaemia 24.13 17.07 63 20471 280215 42320586
Hypoxia 23.90 17.07 81 20453 69705 42531096
Joint swelling 22.62 17.07 3 20531 68019 42532782
Confusional state 22.11 17.07 29 20505 167568 42433233
Pancreatic enzymes increased 21.98 17.07 10 20524 875 42599926
Ketosis 21.77 17.07 10 20524 895 42599906
Pancreatic cyst 21.23 17.07 10 20524 947 42599854
Glycosylated haemoglobin decreased 21.14 17.07 8 20526 439 42600362
Impaired gastric emptying 20.63 17.07 17 20517 4349 42596452
Thyroid adenoma 19.57 17.07 4 20530 19 42600782
Haemoglobin decreased 19.52 17.07 21 20513 132450 42468351
Leukopenia 19.28 17.07 6 20528 74740 42526061
Flatulence 18.72 17.07 39 20495 25113 42575688
Ludwig angina 18.38 17.07 6 20528 212 42600589
Cholecystitis chronic 18.31 17.07 9 20525 936 42599865
Pancreatectomy 17.89 17.07 4 20530 31 42600770
Arthralgia 17.75 17.07 46 20488 205192 42395609
Ductal adenocarcinoma of pancreas 17.46 17.07 4 20530 35 42600766
Thrombosis 17.20 17.07 72 20462 68439 42532362

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 2186.20 14.05 904 35763 92629 110460003
Pancreatitis acute 936.60 14.05 438 36229 59836 110492796
Nausea 653.95 14.05 1327 35340 1234363 109318269
Diabetic ketoacidosis 599.00 14.05 288 36379 41770 110510862
Pancreatic carcinoma 564.61 14.05 205 36462 14667 110537965
Vomiting 378.80 14.05 890 35777 909785 109642847
Lipase increased 353.88 14.05 156 36511 18516 110534116
Blood glucose increased 338.67 14.05 309 36358 132187 110420445
Pulmonary vasculitis 266.09 14.05 95 36572 6465 110546167
Neuritis 262.28 14.05 97 36570 7302 110545330
Pancreatic carcinoma metastatic 246.23 14.05 80 36587 4084 110548548
Diabetes mellitus inadequate control 241.37 14.05 140 36527 29635 110522997
Lactic acidosis 240.07 14.05 218 36449 92593 110460039
Cholelithiasis 223.56 14.05 178 36489 63244 110489388
Eosinophilic granulomatosis with polyangiitis 221.10 14.05 95 36572 10591 110542041
Total lung capacity abnormal 215.13 14.05 74 36593 4509 110548123
Neurological symptom 195.52 14.05 98 36569 15510 110537122
Eructation 193.16 14.05 94 36573 13963 110538669
Glycosylated haemoglobin increased 191.29 14.05 111 36556 23508 110529124
Hypoglycaemia 190.30 14.05 213 36454 115891 110436741
Respiratory symptom 187.69 14.05 94 36573 14851 110537781
Mite allergy 176.41 14.05 68 36599 5735 110546897
Dust allergy 170.67 14.05 67 36600 5934 110546698
Pulmonary alveolar haemorrhage 169.31 14.05 97 36570 20053 110532579
Spirometry abnormal 169.20 14.05 65 36602 5432 110547200
Conjunctivitis allergic 168.10 14.05 69 36598 6862 110545770
Ketoacidosis 167.93 14.05 77 36590 10010 110542622
Mycotic allergy 167.66 14.05 66 36601 5888 110546744
Abdominal pain 166.90 14.05 458 36209 512531 110040101
Diarrhoea 157.45 14.05 769 35898 1138736 109413896
Acute kidney injury 156.37 14.05 514 36153 634916 109917716
Antineutrophil cytoplasmic antibody positive 156.16 14.05 60 36607 5016 110547616
Forced expiratory volume decreased 154.15 14.05 79 36588 13097 110539535
Adenocarcinoma pancreas 148.24 14.05 47 36620 2216 110550416
Weight decreased 134.74 14.05 400 36267 467657 110084975
Normochromic normocytic anaemia 129.21 14.05 70 36597 12987 110539645
Euglycaemic diabetic ketoacidosis 125.39 14.05 66 36601 11557 110541075
Papillary thyroid cancer 125.31 14.05 44 36623 2850 110549782
Injection site erythema 123.17 14.05 154 36513 94022 110458610
Vasculitis 120.67 14.05 98 36569 35775 110516857
Amylase increased 118.02 14.05 65 36602 12454 110540178
Injection site urticaria 108.73 14.05 69 36598 17146 110535486
Hypothyroidism 108.02 14.05 127 36540 72772 110479860
Obstructive airways disorder 106.90 14.05 102 36565 46047 110506585
Arteriosclerosis 105.87 14.05 78 36589 24689 110527943
Dehydration 96.14 14.05 255 36412 279256 110273376
Injection site rash 93.95 14.05 71 36596 23348 110529284
Arteriosclerosis coronary artery 93.86 14.05 73 36594 25045 110527587
Full blood count abnormal 93.78 14.05 104 36563 55948 110496684
Joint swelling 93.41 14.05 17 36650 442828 110109804
Medullary thyroid cancer 93.14 14.05 22 36645 334 110552298
Pancreatitis necrotising 91.59 14.05 42 36625 5459 110547173
Blood glucose decreased 87.64 14.05 75 36592 29413 110523219
Injection site haematoma 84.77 14.05 39 36628 5107 110547525
Nodule 83.03 14.05 76 36591 32555 110520077
Injection site pruritus 82.14 14.05 93 36574 51165 110501467
Decreased appetite 80.05 14.05 341 36326 475505 110077127
Sleep disorder due to a general medical condition 79.21 14.05 92 36575 52020 110500612
Weight loss poor 74.15 14.05 25 36642 1432 110551200
Haemoptysis 72.26 14.05 103 36564 71251 110481381
Capillaritis 72.07 14.05 28 36639 2411 110550221
Febrile neutropenia 71.63 14.05 10 36657 316757 110235875
Infusion related reaction 67.84 14.05 21 36646 381141 110171491
Pyrexia 67.37 14.05 122 36545 898143 109654489
Treatment failure 64.48 14.05 8 36659 277226 110275406
Glossodynia 61.08 14.05 3 36664 222001 110330631
Neutropenia 60.89 14.05 24 36643 374596 110178036
Toxicity to various agents 60.20 14.05 43 36624 480512 110072120
Pancreatic neoplasm 57.62 14.05 22 36645 1807 110550825
Drug ineffective 56.68 14.05 286 36381 1520254 109032378
Pancreatitis chronic 55.81 14.05 28 36639 4437 110548195
Pemphigus 55.69 14.05 4 36663 214566 110338066
Abdominal distension 52.47 14.05 152 36515 174951 110377681
Pneumonia 51.71 14.05 136 36531 876578 109676054
Thyroid neoplasm 51.21 14.05 24 36643 3277 110549355
Hyperglycaemia 51.07 14.05 97 36570 84993 110467639
Flatulence 50.92 14.05 74 36593 52075 110500557
Impaired gastric emptying 50.50 14.05 39 36628 13236 110539396
Thyroid mass 49.44 14.05 27 36640 5086 110547546
Helicobacter infection 48.35 14.05 3 36664 181874 110370758
Arthropathy 47.41 14.05 18 36649 287504 110265128
Pericarditis 47.06 14.05 8 36659 219106 110333526
Drug dose titration not performed 45.37 14.05 16 36651 1049 110551583
Abdominal pain upper 45.24 14.05 232 36435 348879 110203753
Cholecystitis 44.97 14.05 49 36618 25833 110526799
Thrombocytopenia 43.95 14.05 31 36636 348854 110203778
Folliculitis 43.87 14.05 3 36664 167650 110384982
Constipation 43.77 14.05 234 36433 357552 110195080
Contraindicated product administered 43.58 14.05 14 36653 248253 110304379
Pulmonary fibrosis 43.36 14.05 101 36566 101941 110450691
Cholecystitis acute 42.59 14.05 38 36629 15744 110536888
Therapeutic product effect decreased 42.49 14.05 14 36653 244302 110308330
Pancreatic pseudocyst 41.89 14.05 17 36650 1641 110550991
Cholangiocarcinoma 41.77 14.05 20 36647 2865 110549767
Drug abuse 41.54 14.05 5 36662 177406 110375226
White blood cell count decreased 40.15 14.05 13 36654 229377 110323255
Rheumatoid arthritis 39.92 14.05 25 36642 299588 110253044
Thyroid cancer 39.47 14.05 25 36642 6189 110546443
Bile duct stone 39.19 14.05 25 36642 6264 110546368
Respiratory tract haemorrhage 38.70 14.05 17 36650 1997 110550635
Drug intolerance 38.37 14.05 47 36620 406465 110146167
Pain 37.54 14.05 176 36491 954779 109597853
Injury 36.92 14.05 7 36660 177258 110375374
Lower respiratory tract infection 35.67 14.05 18 36649 243088 110309544
Stomatitis 35.39 14.05 23 36644 270219 110282413
Leukopenia 35.31 14.05 4 36663 148787 110403845
Pancreatic carcinoma stage IV 34.00 14.05 16 36651 2204 110550428
Musculoskeletal stiffness 33.76 14.05 26 36641 279796 110272836
C-reactive protein increased 33.72 14.05 15 36652 217904 110334728
Diabetic metabolic decompensation 33.41 14.05 19 36648 3870 110548762
Irritable bowel syndrome 33.12 14.05 7 36660 164208 110388424
Blister 33.12 14.05 17 36650 227359 110325273
Biliary colic 33.01 14.05 20 36647 4577 110548055
Disease progression 33.01 14.05 20 36647 244014 110308618
Glycosylated haemoglobin decreased 33.00 14.05 12 36655 860 110551772
Nasopharyngitis 32.78 14.05 50 36617 394311 110158321
Injection site reaction 32.34 14.05 83 36584 88987 110463645
General physical health deterioration 31.58 14.05 58 36609 425237 110127395
Hepatic enzyme increased 31.45 14.05 36 36631 320856 110231776
Ketosis 31.12 14.05 14 36653 1740 110550892
Cholecystectomy 31.12 14.05 27 36640 10782 110541850
Platelet count decreased 31.01 14.05 19 36648 230424 110322208
Arthralgia 30.43 14.05 144 36523 779488 109773144
Pancreatic mass 30.37 14.05 14 36653 1841 110550791
Mobility decreased 30.02 14.05 21 36646 237401 110315231
Neutrophil count decreased 29.34 14.05 3 36664 120938 110431694
Obstructive pancreatitis 28.89 14.05 12 36655 1229 110551403
Loss of personal independence in daily activities 28.70 14.05 112 36555 149908 110402724
Wound 28.00 14.05 22 36645 234415 110318217
Fibromyalgia 27.66 14.05 11 36656 170898 110381734
Bile acid malabsorption 27.59 14.05 9 36658 465 110552167
Productive cough 27.53 14.05 92 36575 114213 110438419
Reversible cerebral vasoconstriction syndrome 27.39 14.05 18 36649 4743 110547889
Ill-defined disorder 27.24 14.05 9 36658 156844 110395788
Blood glucose abnormal 27.01 14.05 27 36640 12889 110539743
Impaired healing 26.77 14.05 16 36651 196701 110355931
Blood cholesterol increased 26.63 14.05 14 36653 184771 110367861
Infection 26.35 14.05 50 36617 362150 110190482
Type 2 diabetes mellitus 26.18 14.05 13 36654 177219 110375413
Anaemia 25.70 14.05 94 36573 546992 110005640
Drug titration error 25.63 14.05 12 36655 1635 110550997
Malignant neoplasm progression 25.49 14.05 13 36654 174554 110378078
Liver injury 25.48 14.05 9 36658 150404 110402228
Pancreatic enzymes increased 25.07 14.05 12 36655 1717 110550915
Completed suicide 25.06 14.05 26 36641 242355 110310277
Swelling 25.06 14.05 49 36618 350992 110201640
Supraventricular extrasystoles 24.94 14.05 21 36646 8052 110544580
Night sweats 24.51 14.05 7 36660 133976 110418656
Extrasystoles 24.39 14.05 21 36646 8297 110544335
Thrombosis 24.02 14.05 85 36582 108577 110444055
Tonsillar ulcer 23.65 14.05 8 36659 463 110552169
Maternal exposure during pregnancy 23.48 14.05 30 36637 254853 110297779
Bursitis 23.37 14.05 7 36660 129911 110422721
Metastases to liver 23.31 14.05 42 36625 35344 110517288
Blood calcitonin increased 23.00 14.05 5 36662 51 110552581
Pancreatic cyst 22.28 14.05 13 36654 2777 110549855
Medication error 22.28 14.05 4 36663 105362 110447270
Injection site irritation 22.15 14.05 16 36651 4908 110547724
Palpitations 22.14 14.05 108 36559 159104 110393528
Osteoarthritis 21.98 14.05 17 36650 182606 110370026
Asthma 21.84 14.05 150 36517 250141 110302491
Incision site swelling 21.74 14.05 7 36660 347 110552285
Ductal adenocarcinoma of pancreas 21.69 14.05 6 36661 175 110552457
Sinusitis 21.53 14.05 41 36626 296647 110255985
Anxiety 21.37 14.05 191 36476 344887 110207745
Glomerular filtration rate decreased 21.19 14.05 36 36631 28920 110523712
Haemoglobin decreased 21.17 14.05 31 36636 248696 110303936
Hypoxia 21.07 14.05 92 36575 129423 110423209
Injection site hypersensitivity 21.03 14.05 12 36655 2459 110550173
Hyperkalaemia 20.99 14.05 95 36572 135701 110416931
Goitre 20.96 14.05 17 36650 6187 110546445
Product use in unapproved indication 20.92 14.05 77 36590 447300 110105332
Pleural effusion 20.81 14.05 17 36650 177692 110374940
Injection site nodule 20.68 14.05 15 36652 4631 110548001
Non-cardiogenic pulmonary oedema 20.64 14.05 11 36656 1973 110550659
Breath odour 20.60 14.05 11 36656 1981 110550651
Potentiating drug interaction 20.15 14.05 22 36645 11621 110541011
Hypoaesthesia 19.82 14.05 47 36620 314176 110238456
Blood glucose fluctuation 19.72 14.05 18 36649 7680 110544952
Thyroid cyst 19.62 14.05 7 36660 475 110552157
Injection site pain 19.48 14.05 113 36554 177809 110374823
Therapeutic product effect incomplete 19.45 14.05 134 36533 223671 110328961
Gastroenteritis 19.40 14.05 41 36626 38759 110513873
Hypoglycaemic unconsciousness 19.33 14.05 9 36658 1211 110551421
Hepatic steatosis 19.29 14.05 47 36620 48784 110503848
Pancytopenia 18.97 14.05 25 36642 209588 110343044
Ludwig angina 18.90 14.05 6 36661 284 110552348
Hypertension 18.83 14.05 96 36571 509988 110042644
Increased appetite 18.78 14.05 24 36643 14953 110537679
Peripheral swelling 18.58 14.05 70 36597 403964 110148668
Drug level above therapeutic 18.52 14.05 21 36646 11567 110541065
Device lead damage 18.50 14.05 3 36664 4 110552628
Therapy non-responder 18.48 14.05 15 36652 157292 110395340
Pancreatic neuroendocrine tumour 18.42 14.05 8 36659 915 110551717
Diabetic ketosis 18.31 14.05 8 36659 928 110551704
Intentional product use issue 18.21 14.05 34 36633 247872 110304760
Metabolic alkalosis 18.21 14.05 15 36652 5580 110547052
Peripheral venous disease 18.21 14.05 3 36664 84114 110468518
Cancer surgery 17.90 14.05 8 36659 979 110551653
Product contamination with body fluid 17.74 14.05 3 36664 6 110552626
Hyperlipasaemia 17.62 14.05 9 36658 1480 110551152
Benign neoplasm of thyroid gland 17.36 14.05 8 36659 1051 110551581
Diabetic neuropathy 17.22 14.05 16 36651 6983 110545649
Grip strength decreased 17.05 14.05 3 36664 80171 110472461
Renal failure 17.01 14.05 131 36536 226443 110326189
Dyspepsia 16.98 14.05 115 36552 190850 110361782
Genital burning sensation 16.88 14.05 6 36661 403 110552229
Red blood cell sedimentation rate increased 16.50 14.05 3 36664 78299 110474333
Lung disorder 16.36 14.05 109 36558 179938 110372694
Diabetic wound 16.24 14.05 4 36663 73 110552559
Imminent abortion 16.21 14.05 3 36664 12 110552620
Sudden death 16.12 14.05 29 36638 24366 110528266
Drug hypersensitivity 15.90 14.05 87 36580 454003 110098629
Dermoid cyst 15.69 14.05 6 36661 495 110552137
Gastritis 15.48 14.05 46 36621 53653 110498979
Blood ketone body increased 15.48 14.05 7 36660 881 110551751
Optic ischaemic neuropathy 15.37 14.05 12 36655 4135 110548497
Death 15.30 14.05 153 36514 698716 109853916
Follicular thyroid cancer 15.25 14.05 4 36663 95 110552537
Oedema 15.25 14.05 29 36638 209947 110342685
Anuria 14.91 14.05 28 36639 24313 110528319
Diabetic retinopathy 14.72 14.05 11 36656 3553 110549079
Inflammation 14.64 14.05 26 36641 193212 110359420
Abortion spontaneous 14.63 14.05 34 36633 34248 110518384
Hyperchlorhydria 14.46 14.05 9 36658 2160 110550472
Hypercholesterolaemia 14.45 14.05 6 36661 90831 110461801
Musculoskeletal pain 14.44 14.05 24 36643 182999 110369633
Gait disturbance 14.27 14.05 46 36621 278162 110274470
Cytokine release syndrome 14.17 14.05 3 36664 70303 110482329
Arthritis 14.15 14.05 21 36646 167565 110385067
Depressed level of consciousness 14.09 14.05 10 36657 112268 110440364

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10AE56 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, long-acting
ATC A10BJ02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Glucagon-like peptide-1 (GLP-1) analogues
FDA CS M0160181 Glucagon-Like Peptide 1
FDA MoA N0000020058 Glucagon-like Peptide-1 (GLP-1) Agonists
MeSH PA D000097789 Glucagon-Like Peptide-1 Receptor Agonists
MeSH PA D006728 Hormones
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D054795 Incretins
FDA EPC N0000178480 GLP-1 Receptor Agonist
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:63726 neuroprotective agent
CHEBI has role CHEBI:71196 glucagon-like peptide-1 receptor agonist
CHEBI has role CHEBI:74518 anti-obesity agent

Related Drugs by ATC class:

A10AE Insulins and analogues for injection, long-acting 9 drugs
insulin beefinsulin degludecinsulin detemirinsulin glargineinsulin humaninsulin icodecinsulin porklixisenatidesemaglutide
A10BJ Glucagon-like peptide-1 (GLP-1) analogues 5 drugs
albiglutidedulaglutideexenatidelixisenatidesemaglutide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Weight loss indication 89362005
Disorder of thyroid gland contraindication 14304000 DOID:50
Multiple endocrine neoplasia, type 2 contraindication 61808009
Pancreatitis contraindication 75694006 DOID:4989
C-cell hyperplasia of thyroid contraindication 237552009
Hypoglycemic disorder contraindication 237630007
Medullary thyroid carcinoma contraindication 255032005 DOID:3973
Pregnancy, function contraindication 289908002
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.06 acidic
pKa2 3.31 acidic
pKa3 3.67 acidic
pKa4 3.82 acidic
pKa5 4.11 acidic
pKa6 4.44 acidic
pKa7 9.65 acidic
pKa8 11.84 acidic
pKa9 12.2 acidic
pKa10 12.53 acidic
pKa11 12.59 acidic
pKa12 12.81 acidic
pKa13 12.86 acidic
pKa14 12.94 acidic
pKa15 13.1 acidic
pKa16 13.15 acidic
pKa17 13.2 acidic
pKa18 13.29 acidic
pKa19 13.43 acidic
pKa20 13.56 acidic
pKa21 13.56 acidic
pKa22 13.6 acidic
pKa23 13.71 acidic
pKa24 13.82 acidic
pKa25 13.82 acidic
pKa26 13.96 acidic
pKa27 13.97 acidic
pKa28 11.05 Basic
pKa29 10.45 Basic
pKa30 7.87 Basic
pKa31 5.98 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
18MG/3ML (6MG/ML) VICTOZA NOVO NORDISK INC N022341 Jan. 25, 2010 RX SOLUTION SUBCUTANEOUS 9968659 Jan. 9, 2037 METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE
18MG/3ML (6MG/ML) SAXENDA NOVO N206321 Dec. 23, 2014 RX SOLUTION SUBCUTANEOUS 9968659 Jan. 9, 2037 CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
18MG/3ML (6MG/ML) LIRAGLUTIDE TEVA PHARMS A214568 Aug. 27, 2025 RX SOLUTION SUBCUTANEOUS Feb. 24, 2026 PATENT CHALLENGE

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucagon-like peptide 1 receptor GPCR AGONIST EC50 10.20 WOMBAT-PK CHEMBL

External reference:

IDSource
D06404 KEGG_DRUG
4029703 VANDF
C1456408 UMLSCUI
CHEBI:71193 CHEBI
CHEMBL4084119 ChEMBL_ID
D000069450 MESH_DESCRIPTOR_UI
DB06655 DRUGBANK_ID
1133 IUPHAR_LIGAND_ID
8208 INN_ID
839I73S42A UNII
16134956 PUBCHEM_CID
1598264 RXNORM
166619 MMSL
232474 MMSL
232503 MMSL
26647 MMSL
d07466 MMSL
010773 NDDF
444828003 SNOMEDCT_US
444907006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 0143-9144 INJECTION 6 mg SUBCUTANEOUS ANDA 31 sections
Saxenda HUMAN PRESCRIPTION DRUG LABEL 1 0169-2800 INJECTION, SOLUTION 6 mg SUBCUTANEOUS NDA 29 sections
Saxenda HUMAN PRESCRIPTION DRUG LABEL 1 0169-2800 INJECTION, SOLUTION 6 mg SUBCUTANEOUS NDA 29 sections
Xultophy 100/3.6 HUMAN PRESCRIPTION DRUG LABEL 2 0169-2911 INJECTION, SOLUTION 3.60 mg SUBCUTANEOUS BLA 27 sections
Xultophy 100/3.6 HUMAN PRESCRIPTION DRUG LABEL 2 0169-2911 INJECTION, SOLUTION 3.60 mg SUBCUTANEOUS BLA 27 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 0169-4060 INJECTION 6 mg SUBCUTANEOUS NDA 29 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 0169-4060 INJECTION 6 mg SUBCUTANEOUS NDA 29 sections
Liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 0480-3667 INJECTION 6 mg SUBCUTANEOUS NDA authorized generic 29 sections
Liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 0480-7250 INJECTION, SOLUTION 6 mg SUBCUTANEOUS ANDA 29 sections
Liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 14403-3400 INJECTION, SOLUTION 18 mg SUBCUTANEOUS ANDA 18 sections
Liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 14403-3400 INJECTION, SOLUTION 18 mg SUBCUTANEOUS ANDA 18 sections
Liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 14403-3400 INJECTION, SOLUTION 18 mg SUBCUTANEOUS ANDA 18 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 50090-2853 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
Saxenda HUMAN PRESCRIPTION DRUG LABEL 1 50090-4257 INJECTION, SOLUTION 6 mg SUBCUTANEOUS NDA 28 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 50090-4503 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
Liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 50090-7501 INJECTION 6 mg SUBCUTANEOUS NDA authorized generic 28 sections
liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 69097-910 INJECTION, SOLUTION 6 mg SUBCUTANEOUS ANDA 29 sections
LIRAGLUTIDE HUMAN PRESCRIPTION DRUG LABEL 1 69097-920 INJECTION, SOLUTION 6 mg SUBCUTANEOUS ANDA 28 sections
Liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 70377-094 INJECTION 6 mg SUBCUTANEOUS ANDA 29 sections
Liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 70377-095 INJECTION, SOLUTION 6 mg SUBCUTANEOUS ANDA 29 sections
Liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 70748-346 INJECTION 6 mg SUBCUTANEOUS ANDA 26 sections
Liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 70748-346 INJECTION 6 mg SUBCUTANEOUS ANDA 26 sections
Liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 71288-563 INJECTION 6 mg SUBCUTANEOUS ANDA 31 sections
Liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 72603-745 INJECTION 6 mg SUBCUTANEOUS ANDA 31 sections
LIRAGLUTIDE HUMAN PRESCRIPTION DRUG LABEL 1 81607-018 INJECTION, SOLUTION 6 mg SUBCUTANEOUS ANDA 27 sections
liraglutide HUMAN PRESCRIPTION DRUG LABEL 1 81607-019 INJECTION, SOLUTION 6 mg SUBCUTANEOUS ANDA 29 sections